AlphaMedix

DRUG2 trials

Sponsors

Orano Med LLC

Conditions

Neuroendocrine TumorNeuroendocrine Tumors

Phase 1

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

TerminatedNCT03466216

Orano Med LLCNeuroendocrine Tumor

Start: 2018-02-05End: 2023-04-06Updated: 2025-06-10

Phase 2

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Active, not recruitingNCT05153772

Orano Med LLCNeuroendocrine Tumors

Start: 2021-12-21End: 2030-12-01Updated: 2026-04-15

Related Papers

Safety, tolerability and efficacy of <sup>212</sup>Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.

Journal of Clinical Oncology2024-06-0114 citations

Targeted alpha-emitter therapy with <sup>212</sup>Pb-DOTAMTATE in neuroendocrine tumor subjects who progressed following prior <sup>177</sup>Lu/<sup>90</sup>Y-PRRT.

Journal of Clinical Oncology2022-06-013 citations

Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients.

Journal of Clinical Oncology2021-05-2013 citations